Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying leading-edge structural biology and unique machine learning and computational chemistry tools to develop a robust pipeline of novel medicines in immunology, inflammation, and neurology.

Ventus develops differentiated therapies at a fast pace. Using ReSOLVE™, we screened our first target in 2020, selected three development candidates in 2022, advanced our two wholly-owned product candidates into the clinic in 2023, and completed Phase 1 trials for both programs in 2024: VENT-03, a first-in-class cGAS inhibitor, and VENT-02, a best-in-class brain-penetrant NLRP3 inhibitor. In addition, we out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S.

These programs exemplify our unique capabilities and ability to generate first- and best-in-class drugs for immunology and neurology targets, by addressing prevalent diseases with high unmet needs.

Our pipeline and portfolio of discovery programs have been enabled by our proprietary next-generation drug discovery platform, ReSOLVE™. ReSOLVE™ combines the latest advances in machine learning, structural biology, and biophysics to model the full spectrum of protein dynamics, including the precise water networks of a binding pocket, at an unparalleled resolution. This represents the next frontier of structure-based drug discovery/design.